The Major Serum Institute vaccine of India acquired 50% participation in the Cabinet Pharma Packaging Schott Kaisha to become a joint venture partner of the specialized glass company from Germany Schott AG.

The Serum Institute acquired a participation of former co-owners Kaius Dadachanji and Shapoor Mistry, Schott and Serum Institute of India stated in a joint statement.

The joint venture is for pharmaceutical packaging, they added.

The serum institute of India (SII) bought 50% participation in Schott Kaisha to become partner of Schott’s joint venture and reserve of secure pharma packaging, declared the statement.

Partners, however, did not share the financial details of the acquisition of participation by the vaccine.

The joint venture is the main Indian manufacturer of Pharma packaging products such as bottles, syringes, bulbs and cartridges used to pack life rescue medications, in accordance with the declaration.

“Even the best medicine can not reach the patient without the right packaging. Secure this supply chain is of strategic importance. Schott is the ideal partner so that we can do this because of their global expertise and network, “said Adar Poowalla Adar Poonawalla.

As a longtime customer, Serum Institute uses its flasks, bulbs and syringes to store our vaccines, including Covischield. Work even closer is in the best interest in global health, he added.

On the development, the CEO of Schott Frank Heinricht said: “As India has regularly established its position as a global pharmaceutical hub, we are delighted to strengthen our footprint within the Indian Pharmaceutical Supply Chain. We are waiting impatiently with strong pulses of this partnership. “

It is an excellent example of moving to new models of cooperation, with larger synergies between the manufacture of pharmacy and the production of packaging, he added.